STOCKHOLM, Sweden, 25th May 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company's board has resolved to file for bankruptcy on behalf of the Company. The bankruptcy application will be submitted today, 25th May 2025, to the Stockholm District Court. The decision was made after Lipidor yesterday reported […]
STOCKHOLM, Sweden, 24th May 2025 – (Nasdaq First North: LIPI) reports negative results from a Phase III clinical study of the AKP02G2 cutaneous spray for mild to moderate plaque psoriasis. The study, including 294 randomized patients, did not achieve its primary treatment objective of demonstrating at least equivalent therapeutic effect (“non-inferiority”) in the treatment of […]
STOCKHOLM, Sweden, 19th May 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study of AKP02G2 for the treatment of psoriasis has reached “Database Lock” in its clinical development program. The next step is statistical analyses of the data to compile the results. Lipidor will publish […]
STOCKHOLM, Sweden, 9th May 2025 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the financial year 2024. The report is available on the company's website lipidor.se and in the attached pdf (in Swedish). To read the report in full (in Swedish) click here: https://lipidor.se/investors/financial-reports/ The information was provided […]
STOCKHOLM, Sweden, 17th March 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the ongoing Phase III study for the drug candidate AKP02G2 have been randomized. Lipidor now expects study results in the last week of May 2025. The main purpose of the clinical study is to […]
STOCKHOLM, Sweden, 28th February 2025 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January – December 2024. The report is available on the company's website lipidor.se and in the attached pdf. To read the year-end report (in Swedish) click here: https://lipidor.se/investors/financial-reports/ Summary During the year, […]
STOCKHOLM, Sweden, 21st January 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients in the ongoing Phase III study for the drug candidate AKP02G2 have been randomized in the clinical study. The refined forecast now shows results in April 2025. The main purpose of the clinical […]
STOCKHOLM, Sweden, 3rd December 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall have four members, in accordance with the applicable instructions resolved by the Annual General Meeting 2020. The three largest shareholders who are registered with Euroclear Sweden AB on the last of September before […]
STOCKHOLM, Sweden, 20 November 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today provides an update on the business from CEO Ola Holmlund, also announcing a company presentation to take place during Aktiespararna’s National Event in Stockholm next week. Statement from the CEO Due to the fact that Lipidor has switched to […]
STOCKHOLM, Sweden, 24 September 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the first patient has been enrolled in the Phase III clinical study with AKP02G2. The drug candidate AKP02G2 combines calcipotriol and betamethasone and is based on Lipidor's patented AKVANO® technology. The goal of AKP02G2 is to offer […]